Highlights
About
Plasma-derived Protein Therapeutics
Kamada is a plasma-derived protein therapeutics company with a commercial product portfolio and a late-stage clinical pipeline. The company uses its proprietary platform technology and expertise for the extraction and purification of proteins from human plasma.
The company has two FDA-approved products: GLASSIA, intravenous plasma-derived Alpha-1 Antitrypsin (AAT) for the treatment of AAT deficiency, marketed in the United States through a strategic partnership with Shire Plc; and KEDRAB, a rabies immune globulin (human) product distributed in the United States by Kedrion. Kamada also sells an additional four plasma-derived pharmaceutical products in approximately 20 markets.
Kamada has products in late-stage clinical development, including an inhaled formulation of AAT and intravenous AAT for the treatment of type 1 diabetes and GvHD and the prevention of lung transplant rejection.
Identity
| Name | Kamada |
|---|---|
| Slug | kamada |
| Type / kind | startup |
| Crunchbase ID | kamada |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6LoOwKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on TASE on Sep, 2005;Public on NASDAQ on Jun, 2008; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | South District |
| HQ city | Beit Kama |
| HQ address | Beit Kama, Israel |
Web & social
Classifications
Funding
| Total raised | $150.0M |
|---|---|
| Current stage | Public |
| Market cap | $413.9M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}